Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ACCELERON PHARMA INC.

(XLRN)
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Acceleron Pharma : Raymond James Downgrades Acceleron Pharma to Market Perform From Strong Buy

10/04/2021 | 09:05am EST


ę MT Newswires 2021
All news about ACCELERON PHARMA INC.
07:31aBristol Myers Squibb Gets FDA Acceptance of sBLA for Reblozyl
DJ
11/22ACCELERON PHARMA INC.(NASDAQGM : XLRN) dropped from NASDAQ Biotechnology Index
CI
11/22ACCELERON PHARMA : Completion of Acquisition or Disposition of Assets - Form 8-K
PU
11/22ACCELERON PHARMA INC : Completion of Acquisition or Disposition of Assets, Notice of Delis..
AQ
11/22Merck Completes Acceleron Pharma Acquisition
MT
11/22Merck Completes Tender Offer to Acquire Acceleron Pharma Inc.
AQ
11/22Merck Completes Cash Tender Offer to Purchase Acceleron Pharma at $180/Share
MT
11/22ACCELERON PHARMA INC.(NASDAQGM : XLRN) dropped from S&P TMI Index
CI
11/22ACCELERON PHARMA INC.(NASDAQGM : XLRN) dropped from S&P Biotechnology Select Industry Inde..
CI
11/22ACCELERON PHARMA INC.(NASDAQGM : XLRN) dropped from S&P Global BMI Index
CI
More news
Analyst Recommendations on ACCELERON PHARMA INC.
More recommendations
Financials (USD)
Sales 2021
Net income 2021
Net Debt 2021
P/E ratio 2021
Yield 2021
Capitalization 10 932 M 10 932 M -
EV / Sales 2021
EV / Sales 2022 52,9x
Nbr of Employees 312
Free-Float 88,0%
Chart ACCELERON PHARMA INC.
Duration : Period :
Acceleron Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ACCELERON PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Managers and Directors
Habib J. Dable President, Chief Executive Officer & Director
Kevin F. McLaughlin Chief Financial Officer, Treasurer & Senior VP
Francois Nader Non-Executive Chairman
Ravindra Kumar Chief Scientific Officer & Senior Vice President
Jay T. Backstrom Executive VP & Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
ACCELERON PHARMA INC.39.71%10 932
GILEAD SCIENCES, INC.19.58%87 393
BIONTECH SE310.30%80 545
REGENERON PHARMACEUTICALS31.23%66 288
WUXI APPTEC CO., LTD.26.31%65 499
VERTEX PHARMACEUTICALS-13.49%51 982